Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Operating Revenue	131,458	118,131	115,832	123,049	109,439
Other Revenue	2,896	8,323	723.29	-	-
Revenue	134,355	126,454	116,556	123,049	109,439
Revenue Growth (YoY)	6.25%	8.49%	-5.28%	12.44%	2.69%
Cost of Revenue	43,533	45,789	44,108	45,481	38,470
Gross Profit	90,821	80,665	72,448	77,568	70,970
Selling, General & Admin	30,221	34,465	31,833	29,176	28,103
Other Operating Expenses	35,950	25,694	23,541	25,124	21,271
Operating Expenses	71,030	66,208	61,066	59,168	53,809
Operating Income	19,791	14,457	11,382	18,400	17,160
Interest Expense	-2,071	-5,160	-3,490	-2,981	-3,531
Interest & Investment Income	-	61.78	73.52	97.85	29.97
Currency Exchange Gain (Loss)	-	-	2,035	880.54	-752.09
Other Non Operating Income (Expenses)	-	-	-	688.35	468.65
EBT Excluding Unusual Items	17,720	9,359	10,000	17,086	13,376
Gain (Loss) on Sale of Assets	-	15.3	57.25	-64.64	3.54
Legal Settlements	-	-	-8,011	-	-
Other Unusual Items	-3,728	-9,010	351.99	-2,609	445.45
Pretax Income	13,992	364.95	2,398	14,412	13,825
Income Tax Expense	3,521	18,673	3,294	4,476	4,124
Earnings From Continuing Operations	10,471	-18,309	-895.61	9,936	9,701
Earnings From Discontinued Operations	-	3,973	4,670	-	-
Net Income to Company	10,471	-14,335	3,774	9,936	9,701
Minority Interest in Earnings	-0.45	-681.46	-801.55	-519.38	-0.5
Net Income	10,471	-15,017	2,972	9,417	9,700
Net Income to Common	10,471	-15,017	2,972	9,417	9,700
Net Income Growth	-	-	-68.44%	-2.92%	25.01%
Shares Outstanding (Basic)	282	282	282	282	282
Shares Outstanding (Diluted)	282	282	282	282	282
Shares Change (YoY)	0.02%	0.00%	-	-	-
EPS (Basic)	37.11	-53.22	10.53	33.37	34.38
EPS (Diluted)	37.10	-53.22	10.53	33.37	34.38
EPS Growth	-	-	-68.43%	-2.93%	25.01%
Free Cash Flow	-15,772	-11,638	176.29	3,185	3,565
Free Cash Flow Per Share	-55.88	-41.24	0.63	11.29	12.63
Dividend Per Share	2.500	2.500	2.500	2.500	2.500
Gross Margin	67.60%	63.79%	62.16%	63.04%	64.85%
Operating Margin	14.73%	11.43%	9.77%	14.95%	15.68%
Profit Margin	7.79%	-11.88%	2.55%	7.65%	8.86%
Free Cash Flow Margin	-11.74%	-9.20%	0.15%	2.59%	3.26%
EBITDA	24,651	18,297	14,289	19,124	19,448
EBITDA Margin	18.35%	14.47%	12.26%	15.54%	17.77%
D&A For EBITDA	4,860	3,840	2,907	723.93	2,287
EBIT	19,791	14,457	11,382	18,400	17,160
EBIT Margin	14.73%	11.43%	9.77%	14.95%	15.68%
Effective Tax Rate	25.16%	5116.72%	137.34%	31.06%	29.83%
Revenue as Reported	134,355	126,531	118,721	124,716	109,941
Advertising Expenses	-	5,157	5,270	4,349	4,287

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.